Drug Trial Radar · NCT01139749
Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea
Last checked: Nov 20, 2026Latest source record: Oct 12, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 2011
Primary completion
Jul 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Federal University of São PauloAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Oral isotretinoin is the gold standard drug to treat moderate to severe acne. Other indications like seborrhea, seborrheic dermatitis have been suggested. There is risk of reversible mucocutaneous side effects, as well as alterations in lipid profile and transaminases. The major problem is teratogenicity which demands pregnancy control from treatment beginning to one month after treatment end. Seborrhea and seborrheic dermatitis are chronic conditions characterized by oily skin, hair and scalp, erythema, desquamation and negative impact on quality of life. This will be an interventional, therapeutic and quality of life randomized, comparative (parallel groups), blinded evaluation clinical trial, comprising 50 men and women, aged 18 to 40. Treatment with low-dose oral isotretinoin will be compared to topical anti-seborrheic products to evaluate the reduction of sebaceous secretion and colonization of affected areas by yeasts of Malassezia gender. Efficacy will be evaluated by clinical parameters, as well as by sebum secretion measure and application of quality of life questionnaires. Safety will be evaluated by skin hydration measure, side effects report and observation. For subjects using oral isotretinoin blood counting, transaminases, lipid profile and pregnancy test will be requested as selection criteria, on days 30 and 180. Data will be submitted to statistical analysis.
Conditions
- Seborrhea
- Seborrheic Dermatitis
- Quality of Life
Interventions
oral isotretinoinDrug
capsules of 20 mg a day, every other day, for six months
salicylic acid and ciclopirox olamineDrug
Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sebum secretion rateTime frame: day 0
- sebum secretion rateTime frame: day 180
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Federal University of Sao Paulo - Dermatology Department - Cosmetic Dermatology Unit
São Paulo, São Paulo, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.